Next Article in Journal
The Kinase Mirk/dyrk1B: A Possible Therapeutic Target in Pancreatic Cancer
Next Article in Special Issue
A Quest for Initiating Cells of Head and Neck Cancer and Their Treatment
Previous Article in Journal / Special Issue
Models of Hepatocellular Carcinoma and Biomarker Strategy
Article Menu

Export Article

Open AccessReview
Cancers 2010, 2(3), 1453-1491; doi:10.3390/cancers2031453

YKL-40—A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients?

1
Departments of Surgical Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark
2
Departments of Oncology, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark
3
Departments of Medicine, Herlev Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark
*
Author to whom correspondence should be addressed.
Received: 13 May 2010 / Revised: 1 July 2010 / Accepted: 9 July 2010 / Published: 12 July 2010
(This article belongs to the Special Issue Biomarkers: Oncology Studies)
View Full-Text   |   Download PDF [649 KB, uploaded 12 July 2010]   |  

Abstract

YKL-40 is a 40 kDa glycoprotein produced by cancer cells, inflammatory cells and stem cells. It probably has a role in cell proliferation and differentiation, inflammation, protection against apoptosis, stimulation of angiogenesis, and regulation of extracellular tissue remodelling. Plasma levels of YKL-40 are often elevated in patients with localized or advanced cancer compared to age-matched healthy subjects. Several studies have demonstrated that high plasma YKL-40 is an independent prognostic biomarker of short survival in patients with different types of cancer. However, there is not yet sufficient data to support determination of plasma YKL-40 outside research projects as a biomarker for screening of gastrointestinal cancer and determination of treatment response and poor prognosis before or during treatment and follow-up. Plasma YKL-40 is also elevated in patients with other diseases than cancer, e.g., severe infections, cardiovascular disease, diabetes, chronic obstructive lung disease, asthma, liver fibrosis and rheumatoid arthritis. Co-morbidity should therefore always be considered in patients with cancer, since other sources than cancer cells can increase plasma YKL-40 levels. Future focused translational research projects combining basic and clinical research are needed in a joint effort to answer questions of the complex function and regulation of YKL-40 and the question if plasma YKL-40 is a clinical useful biomarker in patients with cancer. View Full-Text
Keywords: biomarker; cancer; CHI3L1; inflammation; YKL-40; tissue remodelling biomarker; cancer; CHI3L1; inflammation; YKL-40; tissue remodelling
Figures

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Schultz, N.A.; Johansen, J.S. YKL-40—A Protein in the Field of Translational Medicine: A Role as a Biomarker in Cancer Patients? Cancers 2010, 2, 1453-1491.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top